CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

Cash and cash equivalents amounted to EUR 392.7 million at the end of June 2025, decreasing from EUR 481.7 million at the end of 2024. In the ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

CureVac's experimental COVID-19 vaccine failed in a pivotal clinical study, the biotech said Wednesday. It's the first late-stage study to flop, with CureVac's vaccine showing 47% effectiveness.

German biotech firm CureVac (5CV.DE) saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting ...

Germany's CureVac (5CV.DE) is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on ...

For CureVac’s co-founder, the biologist Ingmar Hoerr, the company’s Covid-19 vaccine trial is the culmination of a quarter-century’s worth of work with RNA, a molecule that helps turn DNA ...

CureVac had some advantages over the other mRNA vaccines, such as keeping stable for months in a refrigerator. What’s more, compared with its competitors, CureVac’s vaccine used fewer mRNA ...